Table 4.

Demographics, clinical history and laboratory data of RA patients and HCs.

	RA n = 140	HCs n = 137	p value
Age, yrs	59 ± 10	46 (13)	<0.001
Female sex, n (%)	106 (79.3)	90 (65.7)	0.02
Early disease, n (%)	10 (7.2)
ACPA positivity, %	74.1
RF positivity	74.4
HAQ (0–3)	0.83 (0.73)
DAS-28	3.59 ± 1.33
CRP, mg/dL	0.8 ± 1.1
ESR, mm/h	29 ± 24
Steroids therapy, %	41
DMARDs therapy, %	63.3
Anti-TNF therapy, %	25.9
Tocilizumab therapy, %	12.9
Abatacept therapy, %	4.3

Data are expressed as median ± 1 standard deviation. RA duration <12 months is reported as early disease. ACPA: anti-cyclic citrullinated peptide antibodies. RF: rheumatoid factor. HAQ: health assessment questionnaire. DAS-28: Disease Activity Score-28. CRP: C-reactive protein. ESR: erythrocyte sedimentation rate. DMARDs: disease modifying anti-rheumatic drugs. Anti-TNF: anti-tumor necrosis factor alpha.